Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:DERMNASDAQ:DNTHNASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21818,844 shs554,788 shsDERMJourney Medical$6.35+0.6%$6.96$3.54▼$8.25$147M0.8781,998 shs103,461 shsDNTHDianthus Therapeutics$17.44+1.0%$19.23$13.37▼$32.27$555.40M1.36277,623 shs231,928 shsUPBUpstream Bio$10.64+3.2%$9.38$5.14▼$29.46$554.61MN/A335,504 shs605,747 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%0.00%+165.71%DERMJourney Medical-6.38%-13.56%-8.95%+9.74%+13.29%DNTHDianthus Therapeutics-5.21%-7.89%-12.29%-16.12%-31.63%UPBUpstream Bio-7.70%-11.04%+19.33%+20.58%+1,030,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex2.685 of 5 stars3.50.00.04.00.60.01.9DERMJourney Medical2.32 of 5 stars3.62.00.00.01.71.70.6DNTHDianthus Therapeutics1.4777 of 5 stars3.60.00.00.02.01.70.0UPBUpstream Bio2.1783 of 5 stars3.50.00.00.02.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsideDERMJourney Medical 3.20Buy$9.8855.51% UpsideDNTHDianthus Therapeutics 3.13Buy$53.00203.90% UpsideUPBUpstream Bio 3.00Buy$56.50431.02% UpsideCurrent Analyst Ratings BreakdownLatest DERM, CDXC, UPB, and DNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/27/2025DERMJourney MedicalIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.503/27/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00DERMJourney Medical$56.13M2.64N/AN/A$0.91 per share6.98DNTHDianthus Therapeutics$6.24M89.88N/AN/A$11.91 per share1.46UPBUpstream Bio$2.37M241.49N/AN/A$8.77 per share1.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/ADERMJourney Medical-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)DNTHDianthus Therapeutics-$84.97M-$2.88N/AN/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/AN/AN/AN/A8/5/2025 (Estimated)Latest DERM, CDXC, UPB, and DNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million5/6/2025Q1 2025UPBUpstream Bio-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 million3/26/2025Q4 2024DERMJourney Medical-$0.22$0.08+$0.30$0.08$14.21 million$14.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35DERMJourney Medical1.071.341.03DNTHDianthus TherapeuticsN/A15.9815.99UPBUpstream BioN/A47.4347.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%DERMJourney Medical7.25%DNTHDianthus Therapeutics47.53%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%DERMJourney Medical15.03%DNTHDianthus Therapeutics8.15%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionableDERMJourney Medical9023.30 million19.80 millionN/ADNTHDianthus Therapeutics8032.16 million29.54 millionOptionableUPBUpstream Bio3853.79 million46.50 millionN/ADERM, CDXC, UPB, and DNTH HeadlinesRecent News About These CompaniesUpstream Bio (NASDAQ:UPB) Shares Gap Down - What's Next?June 18 at 1:42 PM | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading Down 3.4% - Here's What HappenedJune 16 at 4:45 PM | marketbeat.comUpstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody SpaceJune 16 at 2:16 PM | tipranks.comUpstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher PotencyJune 16 at 12:53 AM | msn.comUpstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI CongressJune 15 at 8:30 AM | quiverquant.comTranslational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP ReceptorJune 15 at 7:45 AM | globenewswire.comUpstream Bio (NASDAQ:UPB) Upgraded at Wall Street ZenJune 9, 2025 | americanbankingnews.comUpstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street ZenJune 7, 2025 | marketbeat.comUpstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025June 5, 2025 | quiverquant.comUpstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025June 5, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Trading Down 3.4% - Should You Sell?June 4, 2025 | marketbeat.comUpstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Trading 10.2% Higher - Here's What HappenedJune 3, 2025 | marketbeat.com1,583,154 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Wellington Management Group LLPJune 1, 2025 | marketbeat.comJane Street Group LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)May 27, 2025 | marketbeat.comNorthern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)May 27, 2025 | marketbeat.comWoodline Partners LP Buys New Stake in Upstream Bio, Inc. (NASDAQ:UPB)May 25, 2025 | marketbeat.comVR Adviser LLC Takes $37.74 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)May 22, 2025 | marketbeat.comUpstream Bio names new chief technology officerMay 21, 2025 | investing.comUpstream Bio Appoints Stacy Price As CTOMay 21, 2025 | nasdaq.comUpstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical OperationsMay 21, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDERM, CDXC, UPB, and DNTH Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Journey Medical NASDAQ:DERM$6.35 +0.04 (+0.63%) Closing price 04:00 PM EasternExtended Trading$6.35 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Dianthus Therapeutics NASDAQ:DNTH$17.44 +0.17 (+0.98%) Closing price 04:00 PM EasternExtended Trading$17.40 -0.05 (-0.26%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Upstream Bio NASDAQ:UPB$10.64 +0.33 (+3.20%) Closing price 04:00 PM EasternExtended Trading$10.64 -0.01 (-0.05%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
